TB Research

Targeted genome sequencing for tuberculosis drug susceptibility testing in South Africa: a proposed diagnostic pipeline

Tayarv Bagratee, David J. Studholme

Access Microbiology · 2024-02

Abstract

In July 2023, the World Health Organization (WHO) began recommending targeted next-generation sequencing (tNGS), due to its ability to detect resistance to many drugs with a single test. In March 2023, South Africa further adopted the GeneXpert XDR cartridge, which detects mutations associated with resistance to second-line injectable drugs. Here, we consider the feasibility for implementing tNGS in South Africa, what such a facility might look like and the specific context of this upper-middle-income country. Whilst the WHO now recommends tNGS for TB diagnostics and DST, there are many economic and infrastructural challenges opposing its deployment. In lieu of this, we instead recommend a stratified diagnostic pipeline that utilizes South Africa’s existing GeneXpert technologies, attempting to reduce the costs associated with implementation of tNGS.

MeSH terms

  • GeneXpert MTB/RIF
  • Tuberculosis
  • Context (archaeology)
  • Medicine
  • Diagnostic test
  • Drug resistant tuberculosis
  • Drug resistance
  • Pipeline (software)
  • Business
  • Environmental health
  • Mycobacterium tuberculosis